首页> 生物试剂> 抗体和免疫分析> ELISA> Edrecolomab ELISA Kit,96T,DB104018-96T,Abinscience

Edrecolomab ELISA Kit,96T,DB104018-96T,Abinscience

销售价: ¥ 6756.00 / 件
在线询价
优    惠: 请询价
订货号 0BC4829
品牌型号 Abinscience DB104018-96T
库存 有库存
最小订货量 1件
联系我们
  • 400-920-3909
AbinscienceELISA其它型号产品
  • 商品介绍
  • 规格参数
  • 包装参数
技术参数 Specifications
Stability and StorageThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection methodColorimetric
Sample typePlasma, Serum
Assay typeQuantitative
Sensitivity0.156 μg/ml
Range0.31-5 μg/mL
Recovery80-120%
BackgroundEdrecolomab, also known as MAb17-1A, is a mouse-derived IgG2a monoclonal antibody targeted at the cell-surface glycoprotein EpCAM (17-1A). This drug was developed by Centocor in an attempt to prevent colorectal cancer and adenocarcinoma. Edrecolomab has been investigated in the clinical trials for the treatment of colon cancer. Edrecolomab was licensed as an adjuvant therapy for postoperative colorectal cancer by German authorities with the trade name Panorex in 1995. However, in 2004, researchers applied edrecolomab to the study of postoperative adjuvant therapy in patients with colorectal cancer. The results showed that edrecolomab adjuvant therapy can help Dukes'CCRC patients to restore the lack of immune response in the body, but the randomized trials of clinical efficacy were unsatisfactory. Then in 2005, Edrecolomab was studied in a phase 3 randomized trial of postoperative adjuvant therapy for colorectal cancer. However, the results showed that Edrecolomab did not improve overall survival or disease-free survival in patients with stage II colon cancer treated with postoperative adjuvant therapy. Subsequently, Edrecolomab in combination with fluorouracil (FU) was used to treat colorectal cancer in the III stage. However, the results showed that the addition of ED in the basic treatment of fluorouracil had no significant effect on OS. Edrecolomab also did not prolong patient survival in subsequent randomized trials. Although Edrecolomab has not shown very good results in previous studies of colorectal cancer, it is still a promising monoclonal antibody for the treatment of adenocarcinomas expressing EpCAM.
Alternative Names17-1A, CAS: 156586-89-9
Shipping2-8 ℃
SpecificationsEdrecolomab
NoteFor Research Use Only.
长度(mm)
宽度(mm)
高度(mm)
重量(kg)
猜你喜欢

在线
客服

在线客服服务时间:09:00-18:00

客服
热线

400-920-3909
客服服务热线 周一至周五(09:00-18:00)

微信
咨询

微信小程序 7X24小时在线咨询